Spectroscopic studies on the membrane lipids of mammalian cells.

L. Guidoni,F. Ianzini,A. Rosi,V. Viti

Abstract:

What problem does this paper attempt to address?

Glucocorticoid Receptor as a Potential Target to Decrease Aromatase Expression and Inhibit Leydig Tumor Growth.

S. Panza,R. Malivindi,Francesca Chemi,V. Rago,C. Giordano,I. Barone,D. Bonofiglio,L. Gelsomino,F. Giordano,S. Andò,S. Catalano

DOI: https://doi.org/10.1016/j.ajpath.2015.12.024

IF: 5.77

2016-05-01

American Journal Of Pathology

Abstract:
Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide

Marc Sherwin,Joshua Hamburger,Daniel Katz,Samuel DeMaria

DOI: https://doi.org/10.1007/s12630-023-02549-5

2023-07-21

Canadian Journal of Anaesthesia

Abstract:Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) have become increasingly popular as both diabetic and weight loss therapies. One effect of this class of medication is delayed gastric emptying, which may impact the risk of aspiration during anesthesia delivery.
Anesthesia Considerations for a Patient on Semaglutide and Delayed Gastric Emptying

Erina Fujino,Kathryn W Cobb,Jay Schoenherr,Lindsey Gouker,Elisa Lund

DOI: https://doi.org/10.7759/cureus.42153

2023-07-19

Cureus

Abstract:Semaglutide is a class of long-acting glucagon-like peptide-1 receptor agonists (GLP1-RA) used for the treatment of type 2 diabetes mellitus (T2DM) and obesity. We present a 31-year-old female patient with a past medical history of T2DM without complication and no long-term or current use of insulin, class 3 obesity, hypertension, hyperlipidemia, polycystic ovary syndrome (PCOS), and anxiety, who underwent an esophagogastroduodenoscopy (EGD) in preparation for bariatric surgery while taking semaglutide. Despite appropriately following the preoperative fasting guidelines of the American Society of Anesthesiologists (ASA), endoscopy revealed food residue in the gastric body, necessitating abortion of the procedure to reduce the risk of intraoperative pulmonary aspiration. Given the lack of preoperative fasting guidelines for patients on semaglutide to date, and delayed gastric emptying being a known side effect among patients taking semaglutide, anesthesiologists should be aware of alternative methods to ensure no food is present in the stomach to mitigate the risk of pulmonary aspiration during general anesthesia.
Survival of chromium-51-labeled erythrocytes in the rhesus monkey.

C. Glomski,R. E. Hagle,S. Pillay

American Journal of Veterinary Research

Abstract:
[Diagnostic value of echotomography in aneurysms of the abdominal aorta].

G. Magnani,R. Mandrioli,U. Ugolotti,E. Banchini,P. Salcuni

1978-02-28

Minerva Chirurgica

Abstract:
Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report

Michael A. Gulak,Patricia Murphy

DOI: https://doi.org/10.1007/s12630-023-02521-3

2023-06-08

Canadian Journal of Anaesthesia

Abstract:Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide are a class of medications prescribed to treat type 2 diabetes mellitus, and more recently, as an adjunct for weight loss because of its effects of delaying gastric emptying and suppressing appetite. Semaglutide is a long-acting agent with a half-life of approximately one week, and there are currently no guidelines that address the perioperative management of such agents.
VARLAe AUCTORITATIS.

C. Eastman

DOI: https://doi.org/10.1126/science.20.502.215-a

IF: 56.9

Science

Abstract:
Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report

Sandra R. Klein,Ion A. Hobai

DOI: https://doi.org/10.1007/s12630-023-02440-3

2023-03-30

Canadian Journal of Anaesthesia

Abstract:We report a case in which the use of semaglutide for weight loss was associated with delayed gastric emptying and intraoperative pulmonary aspiration of gastric contents.
[Diagnosis and treatment of eosinophilic paranasal sinusitis].

Shigeharu Fijieda,M. Sakashita,Y. Imoto,Takahiro Tokunaga,Takahiro Ninomiya

DOI: https://doi.org/10.3950/JIBIINKOKA.117.96

2014-02-01

Abstract:
Management of advanced stage intermediate grade non‐Hodgkin's lymphomas

R. Liang,R. Liang,E. Chiu,T. Chan,D. Todd,S. Loke

DOI: https://doi.org/10.1002/hon.2900080306

IF: 4.85

2006-10-01

Hematological Oncology

Abstract:The treatment result of 271 cases of advanced stage intermediate grade lymphoma were reviewed. Ninety‐four patients received CHOP chemotherapy, 45 BACOP and 17 m‐BACOD. The clinical characteristics of the three groups of patients were comparable. Patients receiving CHOP had a complete response (CR) rate of 60 per cent, the disease‐free survival of CR patients was 31 per cent at 5 years. The overall survival following CHOP chemotherapy was 38 per cent at 5 years. The use of the BACOP or m‐BACOD regime did not appear to improve significantly the prognosis of these patients. Clinical staging, B symptoms, age and serum lactate dehydrogenase level were the most important independent prognostic factors.
Optimizing Therapeutic Outcomes With Oral Semaglutide: A Patient-Centered Approach

Diana M Isaacs,Davida F Kruger,Geralyn R Spollett,Diana M. Isaacs,Davida F. Kruger,Geralyn R. Spollett

DOI: https://doi.org/10.2337/ds20-0016

2021-02-01

Diabetes Spectrum

Abstract:In September 2019, the U.S. Food and Drug Administration approved oral semaglutide as the first orally administered glucagon-like peptide 1 (GLP-1) receptor agonist for treating people with type 2 diabetes. Although injectable GLP-1 receptor agonists are well-established treatment options for people with type 2 diabetes, clinical experience with an oral formulation in this class is limited. This article provides practical guidance for diabetes care and education specialists on how to effectively counsel patients initiating therapy with oral semaglutide on appropriate administration of the treatment and its possible effects on glycemic control, body weight, and quality of life. Strategies for mitigating potential side effects typical of the GLP-1 receptor agonist class, namely nausea, vomiting, and diarrhea, are also provided. Involving patients in treatment decisions and educating them about available and prescribed medications are key strategies for encouraging treatment adherence and ensuring optimal therapeutic outcomes.
Gastric point-of-care ultrasonography in patients undergoing radical gastrointestinal surgery before anesthetic induction: an observational cohort study

Siming Huang,Shumei Cao,Xia Sun,Jun Zhang

DOI: https://doi.org/10.1186/s12871-024-02473-1

IF: 2.376

2024-03-05

BMC Anesthesiology

Abstract:Pulmonary aspiration of gastric contents is a serious perioperative complication. Patients with gastric cancer may experience delayed gastric emptying. However, the role of qualitative and quantitative gastric ultrasound assessments in this patient population before anesthesia induction has not yet been determined.

anesthesiology
Acute Pancreatitis Likely Due to Semaglutide

Katie Hughes,Yovan Ram Kurrun Sumaruth,Elmahi Mohammed,Vibhootee Sant Bakshsingh

DOI: https://doi.org/10.7759/cureus.69844

2024-09-21

Cureus

Abstract:Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) that has gained recent popularity in its effective management of type 2 diabetes mellitus (T2DM) and obesity. Minimal evidence has reported the link between Semaglutide use and acute pancreatitis. In this case report, we discuss the case of a 36-year-old female presenting to the Emergency Department with sudden-onset epigastric pain, subsequently diagnosed with acute pancreatitis. Moreover, she had recently started subcutaneous semaglutide injections for weight loss, which she had procured from one of her acquaintances without seeking medical advice. Semaglutide was thus stopped and her lipase levels normalized with significant improvement of her symptoms, making semaglutide the likely causative factor for her acute pancreatitis. Given the increased use of GLP-1RA, we aim to increase awareness among patients taking this medication whether prescribed or not and increase clinician awareness when prescribing this medication.
Challenges with a glucagon-like peptide-1 (GLP-1) agonist initiation: a case series of semaglutide overdose administration errors

Brian G. Wiener,Marlis Gnirke,Susi Vassallo,Silas W. Smith,Mark K. Su

DOI: https://doi.org/10.1080/15563650.2024.2322049

2024-03-14

Clinical Toxicology

Abstract:Background Prescriptions of semaglutide, a glucagon-like peptide-1 receptor agonist administered weekly for Type 2 diabetes mellitus and obesity, are increasing. Adverse effects from semaglutide overdose are poorly described. We report adverse effects from three unintentional semaglutide overdoses upon initiation.

toxicology
Isolation and characterization of the complete human β-myosin heavy chain gene

K. W. Diederich,I. Eisele,T. Ried,T. Jaenicke,P. Lichter,H. Vosberg

DOI: https://doi.org/10.1007/BF00278991

1989-02-01

Human Genetics

Abstract:
A Review and Illustrative Case of an Adverse Effect of GLP-1 Receptor Agonist

Abby R. Goron,Courtney Connolly,Arielle N. Valdez-Sinon,Ashley Hesson,Christine Helou,Gregory W. Kirschen

DOI: https://doi.org/10.3390/jcm13206259

IF: 3.9

2024-10-21

Journal of Clinical Medicine

Abstract:A host of anti-hyperglycemic agents are currently available and widely prescribed for diabetes and weight loss management. In patients undergoing surgery, use of these agents poses a clinical challenge to surgeons, anesthesiologists, and other perioperative care providers with regard to optimal timing of discontinuation and resumption of use, as well as possible effects of these agents on physiology and risk of postoperative complications. Here, we provide a comprehensive review of anti-hyperglycemic medications' effects on physiology, risks/benefits, and best practice management in the perioperative setting. Additionally, we report an illustrative case of small bowel obstruction in a patient taking semaglutide for 6 months prior to an otherwise uncomplicated laparoscopic hysterectomy and bilateral salpingo-oophorectomy. This review is meant to serve not as a replacement of, but rather as a consolidated complement to, various society guidelines regarding perioperative anti-hyperglycemic agent management.

medicine, general & internal
S4698 Esophageal Obstruction Secondary to Severe Gastroduodenal Retention in the Setting of Recent Semaglutide Initiation

Ali A. Aijaz,Navpreet Rana,Matthew J. Hudson

DOI: https://doi.org/10.14309/01.ajg.0001048160.95530.8a

2024-10-26

The American Journal of Gastroenterology

Abstract:The use of glucagon-like peptide-1 receptor agonists (GLP-1RA) for diabetes and weight loss has been increasing worldwide, and this will likely continue to accelerate in the coming years. Nausea and vomiting are known adverse effects of GLP-1RAs and previous studies showed that their use delays gastric emptying with associated gastric residue. We present a unique case of symptomatic obstruction of the thoracic esophagus due to a large phytobezoar in the context of recent initiation of a GLP-1RA in a previously asymptomatic patient.

gastroenterology & hepatology
Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist

John D Bucheit,Lauren G Pamulapati,Nicole Carter,Kevin Malloy,Dave L Dixon,Evan M Sisson

DOI: https://doi.org/10.1089/dia.2019.0185

Abstract:Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are highly effective at lowering hemoglobin A1c (HbA1c) and facilitating weight loss. Four agents in the GLP-1 RA class, albiglutide, liraglutide, dulaglutide, and semaglutide, also have cardioprotective effects. However, subcutaneous administration of these agents remains a major reason for their underutilization. A new coformulation of semaglutide with sodium N-[8-(2-hydroxybenzoyl) amino caprylate (SNAC) is the first oral GLP-1 RA reviewed by the U.S. Food and Drug Administration (FDA). The SNAC technology prevents destruction of semaglutide in the stomach and facilitates transcellular absorption through the gastric membrane enabling semaglutide to reach systemic circulation intact. The oral formulation of semaglutide was studied in the PIONEER trials, demonstrating similar efficacy to the presently available GLP-1 RAs with regard to HbA1c lowering and weight loss. Although the PIONEER 6 trial suggests positive effects on cardiovascular mortality with oral semaglutide, these benefits may not fully be appreciated until the completion of the SOUL trial.
Disseminated Mucor infection and thrombotic microangiopathy in lymphoma-associated hemophagocytic syndrome

Naoko Inagaki,K. Sugimoto,M. Hosone,Y. Isobe,Yuko Yamamoto,M. Sasaki,A. Kato,Takeshi Mori,K. Oshimi

DOI: https://doi.org/10.1007/s12185-008-0156-6

2008-09-06

International Journal of Hematology

Abstract:
Exocrine Pancreatic Insufficiency During the Use of Semaglutide: A Case Report

Clivaldo Agra de Melo Junior,Norberto Eloi Gomes Júnior,Marco Aurélio da Silva Ribeiro-Sousa,Selma Freire de Carvalho Cunha

DOI: https://doi.org/10.7759/cureus.55549

2024-03-05

Cureus

Abstract:Although acute pancreatitis has been reported as an adverse event in patients treated with glucagon-like peptide-1 (GLP-1) analogues, to date we have not identified a case describing exocrine pancreatic insufficiency related to this drug. Here we present a case of a patient with no history of acute pancreatitis, who was diagnosed with exocrine pancreatic insufficiency during the third year of weekly subcutaneous semaglutide for obesity control. A 68-year-old man with previous unsuccessful therapeutic approaches for weight loss used subcutaneous semaglutide, once a week, for 181 weeks. The pharmacological treatment, combined with instructions on lifestyle changes, resulted in a weight loss of 11.6% of initial body weight, with a reduction in body mass index from 35.7 to 31.9 kg/m2. The patient received a regular dose of 0.5mg/week in the first 14 weeks in a private physician's office. During this period, an asymptomatic elevation of serum lipase was identified and attributed to alcohol consumption. Because the patient complained of less satiety and weight loss stabilization, the dose of semaglutide was increased to 1.0mg/week. Serum lipase levels increased to up to eight times the upper normal limit and the use of semaglutide was discontinued for 10 weeks. Due to progressive weight regain and serum lipase levels being near normal, semaglutide was reintroduced at 0.25mg/week with progressive increments until 1.0mg/week. The patient missed the follow-up appointments, continued the same dose of semaglutide for another 16 weeks, and discontinued treatment after another asymptomatic elevation in serum lipase levels. Four weeks later, the patient reported steatorrhea and was seen by a gastroenterologist, who diagnosed exocrine pancreatic insufficiency. The course of our case suggests a potential association between semaglutide and chronic alcohol consumption in the development of exogenous pancreatic insufficiency. We call attention to the importance of regular monitoring of serum lipase levels in patients taking GLP-1 analogues and suggest that the consumption of any amount of alcohol should be discouraged in patients in long-term treatment with glucagon-like peptide-1 receptor agonists.

Spectroscopic studies on the membrane lipids of mammalian cells.

Glucocorticoid Receptor as a Potential Target to Decrease Aromatase Expression and Inhibit Leydig Tumor Growth.

Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide

Anesthesia Considerations for a Patient on Semaglutide and Delayed Gastric Emptying

Survival of chromium-51-labeled erythrocytes in the rhesus monkey.

[Diagnostic value of echotomography in aneurysms of the abdominal aorta].

Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report

VARLAe AUCTORITATIS.

Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report

[Diagnosis and treatment of eosinophilic paranasal sinusitis].

Management of advanced stage intermediate grade non‐Hodgkin's lymphomas

Optimizing Therapeutic Outcomes With Oral Semaglutide: A Patient-Centered Approach

Gastric point-of-care ultrasonography in patients undergoing radical gastrointestinal surgery before anesthetic induction: an observational cohort study

Acute Pancreatitis Likely Due to Semaglutide

Challenges with a glucagon-like peptide-1 (GLP-1) agonist initiation: a case series of semaglutide overdose administration errors

Isolation and characterization of the complete human β-myosin heavy chain gene

A Review and Illustrative Case of an Adverse Effect of GLP-1 Receptor Agonist

S4698 Esophageal Obstruction Secondary to Severe Gastroduodenal Retention in the Setting of Recent Semaglutide Initiation

Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist

Disseminated Mucor infection and thrombotic microangiopathy in lymphoma-associated hemophagocytic syndrome

Exocrine Pancreatic Insufficiency During the Use of Semaglutide: A Case Report